Agilent SureSelect Human All Exon V6, V6+UTR, and V6+COSMIC

Agilent Technologies has added the SureSelect Human All Exon V6, V6+UTR, and V6+COSMIC to its line of target-enrichment products. The new products are designed to address the limitations of exome sequencing, targeting hard-to-capture and multi-mapping regions. The products also increase the sensitivity of variant calling and minimize false negative calls, Agilent said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.